September 07, 2010
Somaxon announced that Silenor (doxepin tablets) has been made available for the treatment of insomnia characterized by difficulty with sleep maintenance.
May 11, 2010
The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.
March 18, 2010
The FDA has approved Silenor (doxepin tablets, from Somaxon Pharmaceuticals) for the treatment of insomnia characterized by difficulty with sleep maintenance.
January 26, 2010
FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).
January 15, 2010
McNeil Consumer Healthcare and the FDA have announced a voluntary recall of certain lots of over-the-counter products, including Tylenol (acetaminophen), Motrin IB (ibuprofen), St. Joseph Aspirin (aspirin), Simply Sleep (diphenhydramine), and Rolaids (calcium carbonate and magnesium hydroxide).